Imlunestrant Clinical Data: Insights From the EMBER and EMBER-3 Trials

Video content above is prompted by the following:

• Please provide an overview of the EMBER trial study design, arms, and high-level takeaways from the following:
  • EMBER phase 1b: imlunestrant plus or minus everolimus or alpelisib
  • EMBER phase 1b: imlunestrant plus abemaciclib plus or minus aromatase inhibitor
• Please provide some background on the EMBER-3 trial investigating imlunestrant plus or minus abemaciclib in ER+/HER2– ABC pretreated with endocrine therapy plus or minus CDK4/6 inhibitor.
  • Please provide an overview of major efficacy and safety end points from EMBER-3 as well as subgroup data from the trial.